ATE494912T1 - Mnk-kinase-homologe proteine, die an der regulierung der energiehomöostase und dem organellen metabolismus beteiligt sind - Google Patents
Mnk-kinase-homologe proteine, die an der regulierung der energiehomöostase und dem organellen metabolismus beteiligt sindInfo
- Publication number
- ATE494912T1 ATE494912T1 AT02802306T AT02802306T ATE494912T1 AT E494912 T1 ATE494912 T1 AT E494912T1 AT 02802306 T AT02802306 T AT 02802306T AT 02802306 T AT02802306 T AT 02802306T AT E494912 T1 ATE494912 T1 AT E494912T1
- Authority
- AT
- Austria
- Prior art keywords
- metabolism
- disorders
- energy homeostasis
- regulation
- organal
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 230000004060 metabolic process Effects 0.000 title abstract 2
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
- 230000009892 regulation of energy homeostasis Effects 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract 2
- 206010006895 Cachexia Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 230000006583 body weight regulation Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000001883 cholelithiasis Diseases 0.000 abstract 1
- 208000029078 coronary artery disease Diseases 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 230000019439 energy homeostasis Effects 0.000 abstract 1
- 208000001130 gallstones Diseases 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 210000003463 organelle Anatomy 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 230000001850 reproductive effect Effects 0.000 abstract 1
- 201000002859 sleep apnea Diseases 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 230000035924 thermogenesis Effects 0.000 abstract 1
- 150000003626 triacylglycerols Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01125812 | 2001-10-29 | ||
| EP02011073 | 2002-05-17 | ||
| PCT/EP2002/012075 WO2003037362A2 (en) | 2001-10-29 | 2002-10-29 | Mnk kinase homologous proteins involved in the regulation of energy homeostasis and organelle metabolism |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE494912T1 true ATE494912T1 (de) | 2011-01-15 |
Family
ID=26076753
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02802306T ATE494912T1 (de) | 2001-10-29 | 2002-10-29 | Mnk-kinase-homologe proteine, die an der regulierung der energiehomöostase und dem organellen metabolismus beteiligt sind |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US20050080026A1 (de) |
| EP (2) | EP1439863B1 (de) |
| JP (2) | JP4518378B2 (de) |
| AT (1) | ATE494912T1 (de) |
| AU (1) | AU2002363175A1 (de) |
| DE (2) | DE10294485T5 (de) |
| DK (1) | DK1439863T3 (de) |
| WO (1) | WO2003037362A2 (de) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1856252B1 (de) * | 2005-03-08 | 2014-11-26 | Boehringer Ingelheim International GmbH | KRISTALLOGRAPHISCHE STRUKTUR DES MNK-1 und MNK-2 PROTEINS |
| EP1899353A1 (de) * | 2005-06-22 | 2008-03-19 | DeveloGen Aktiengesellschaft | Thienopyrimidine für pharmazeutische zusammensetzungen |
| CN101454325A (zh) | 2006-03-09 | 2009-06-10 | 法马科皮亚公司 | 用于治疗代谢性疾病的8-杂芳基嘌呤mnk2抑制剂 |
| CN101466716A (zh) * | 2006-04-07 | 2009-06-24 | 德维洛根股份公司 | 用于药物组合物的具有mnkl/mnk2抑制活性的噻吩并嘧啶 |
| EP1889847A1 (de) | 2006-07-10 | 2008-02-20 | DeveloGen Aktiengesellschaft | Pyrrolopyrimidine zur pharmazeutischen Anwendung |
| AU2009286734A1 (en) | 2008-08-26 | 2010-03-04 | Boehringer Ingelheim International Gmbh | Thienopyrimidines for pharmaceutical compositions |
| US8476227B2 (en) | 2010-01-22 | 2013-07-02 | Ethicon Endo-Surgery, Inc. | Methods of activating a melanocortin-4 receptor pathway in obese subjects |
| US9044606B2 (en) | 2010-01-22 | 2015-06-02 | Ethicon Endo-Surgery, Inc. | Methods and devices for activating brown adipose tissue using electrical energy |
| PH12012501693A1 (en) | 2010-02-26 | 2012-11-05 | Boehringer Ingelheim Int | 4 - [cycloalkyloxy (hetero) arylamino] thieno [2,3 - d] pyrimidines having mnkl/mnk2 inhibiting activity for pharmaceutical compositions |
| EP2539344B1 (de) | 2010-02-26 | 2014-10-15 | Boehringer Ingelheim International GmbH | Halogen oder cyano substituierte thieno[2,3-d]pyrimidine mit mnk1/mnk2-hemmender wirkung für pharmazeutische zusammensetzungen |
| UY33241A (es) | 2010-02-26 | 2011-09-30 | Boehringer Ingelheim Int | ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?. |
| BR112012021453A2 (pt) | 2010-02-26 | 2017-02-21 | Boehringer Ingelheim Int | tienopirimidina, sua composição farmacêutica e seu uso |
| ES2635262T3 (es) | 2012-11-09 | 2017-10-03 | Evotec International Gmbh | Quinazolinas sustituidas con sulfoximina para composiciones farmacéuticas |
| AU2014359456B2 (en) | 2013-12-04 | 2019-01-24 | Evotec International Gmbh | Sulfoximine substituted quinazolines for pharmaceutical compositions |
| WO2015091156A1 (en) | 2013-12-17 | 2015-06-25 | Boehringer Ingelheim International Gmbh | Sulfoximine substituted pyrrolotriazines for pharmaceutical compositions |
| US10373257B1 (en) * | 2014-02-21 | 2019-08-06 | Arity International Limited | Vehicle telematics and account management |
| CA2944103A1 (en) | 2014-05-07 | 2015-11-12 | Evotec International Gmbh | Sulfoximine substituted quinazolines for pharmaceutical compositions |
| US10092738B2 (en) | 2014-12-29 | 2018-10-09 | Ethicon Llc | Methods and devices for inhibiting nerves when activating brown adipose tissue |
| US10080884B2 (en) | 2014-12-29 | 2018-09-25 | Ethicon Llc | Methods and devices for activating brown adipose tissue using electrical energy |
| MX2018004879A (es) | 2015-10-22 | 2019-02-28 | Selvita S A | Nuevos derivados de piridona y su uso como inhibidores de quinasas. |
| US10851082B2 (en) | 2015-10-28 | 2020-12-01 | Northwestern University | Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (MNK1) and 2 (MNK2) |
| WO2017075367A1 (en) | 2015-10-28 | 2017-05-04 | Northwestern University | Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (mnk1) and 2 (mnk2) |
| EP3564235A1 (de) | 2018-05-03 | 2019-11-06 | Northwestern University | Substituierte aromatische n-heterocyclische verbindungen als inhibitoren der mitogen-aktivierten proteinkinase-interagierenden kinase 1 (mnk1) und 2 (mnk2) |
| EP3663404A1 (de) * | 2018-12-03 | 2020-06-10 | Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal | Aptamere und verwendung davon in der behandlung von krebs |
| US11411349B1 (en) | 2021-05-12 | 2022-08-09 | Carlisle Interconnect Technologies, Inc. | Electrical connector assembly with RF impedance element |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
| JPS60185719A (ja) | 1984-03-06 | 1985-09-21 | Ajinomoto Co Inc | 抗腫瘍剤 |
| US4952567A (en) * | 1988-05-09 | 1990-08-28 | City Of Hope | Inhibition of lipogenesis |
| WO1995006411A1 (en) * | 1993-08-30 | 1995-03-09 | Lipocyte, Inc. | Method and composition for weight reduction |
| AU711592B2 (en) | 1995-04-03 | 1999-10-14 | Novartis Ag | Pyrazole derivatives and processes for the preparation thereof |
| US5658903A (en) * | 1995-06-07 | 1997-08-19 | Smithkline Beecham Corporation | Imidazole compounds, compositions and use |
| ZA967892B (en) * | 1995-09-21 | 1998-03-18 | Lilly Co Eli | Selective β3 adrenergic agonists. |
| CA2274593A1 (en) | 1996-12-13 | 1998-06-18 | Banyu Pharmaceutical Co., Ltd. | Novel aminopyrazole derivatives |
| PL336990A1 (en) * | 1997-05-22 | 2000-07-31 | Searle & Co | 3(5)-heteroaryl group substituted pyrazoles as inhibitors of kinase p 38 |
| CO4940430A1 (es) | 1997-07-07 | 2000-07-24 | Novartis Ag | Compuestos policiclicos que contienen estaurosporina hidrogenada con propiedades farmacologicas convenientes y un efecto inhibidor sobre el crecimiento de las celulas tumorales |
| CA2369156A1 (en) * | 1999-04-09 | 2000-10-19 | Nahum Sonenberg | Non-human transgenic animal whose germ cells and somatic cells contain a knockout mutation in dna encoding 4e-bp1 |
| CN1301870A (zh) * | 1999-12-29 | 2001-07-04 | 国家人类基因组南方研究中心 | 新的人促分裂原活化蛋白激酶相关蛋白激酶及其编码序列 |
| JP2005500813A (ja) * | 2001-01-12 | 2005-01-13 | エクセリクシス・インコーポレイテッド | インスリン受容体シグナル伝達の調節 |
| SE0102147D0 (sv) * | 2001-06-18 | 2001-06-18 | Pharmacia Ab | New methods |
| US7468431B2 (en) * | 2004-01-22 | 2008-12-23 | Isis Pharmaceuticals, Inc. | Modulation of eIF4E-BP2 expression |
| EP1746099A1 (de) | 2004-12-23 | 2007-01-24 | DeveloGen Aktiengesellschaft | Mnk1 or Mnk2 Inhibitoren |
| EA013821B1 (ru) * | 2005-05-25 | 2010-08-30 | Кьюрдм, Инк. | Проостровковые пептиды человека, их производные и аналоги и способы их применения |
| US20100322906A1 (en) * | 2005-10-05 | 2010-12-23 | Osaka University | Method for Obtaining Pancreatic Endocrine Cells From Adipose Tissue-Origin Cells |
| AU2009332930A1 (en) * | 2008-02-01 | 2009-08-13 | The Scripps Research Institute | Methods for treating a condition characterized by dysfunction in protein homeostasis |
| EP2539344B1 (de) * | 2010-02-26 | 2014-10-15 | Boehringer Ingelheim International GmbH | Halogen oder cyano substituierte thieno[2,3-d]pyrimidine mit mnk1/mnk2-hemmender wirkung für pharmazeutische zusammensetzungen |
-
2002
- 2002-10-29 DE DE10294485T patent/DE10294485T5/de not_active Ceased
- 2002-10-29 US US10/494,010 patent/US20050080026A1/en not_active Abandoned
- 2002-10-29 EP EP02802306A patent/EP1439863B1/de not_active Expired - Lifetime
- 2002-10-29 EP EP20100178471 patent/EP2277552A1/de not_active Withdrawn
- 2002-10-29 AT AT02802306T patent/ATE494912T1/de active
- 2002-10-29 DE DE60238929T patent/DE60238929D1/de not_active Expired - Lifetime
- 2002-10-29 DK DK02802306.7T patent/DK1439863T3/da active
- 2002-10-29 JP JP2003539705A patent/JP4518378B2/ja not_active Expired - Fee Related
- 2002-10-29 WO PCT/EP2002/012075 patent/WO2003037362A2/en not_active Ceased
- 2002-10-29 AU AU2002363175A patent/AU2002363175A1/en not_active Abandoned
-
2008
- 2008-07-16 US US12/174,301 patent/US8076098B2/en not_active Expired - Fee Related
-
2010
- 2010-03-12 JP JP2010056183A patent/JP5185962B2/ja not_active Expired - Fee Related
-
2011
- 2011-09-26 US US13/245,188 patent/US8828934B2/en not_active Expired - Fee Related
- 2011-09-26 US US13/245,113 patent/US8957020B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003037362A3 (en) | 2003-12-24 |
| US20120045451A1 (en) | 2012-02-23 |
| JP4518378B2 (ja) | 2010-08-04 |
| EP2277552A1 (de) | 2011-01-26 |
| JP2010119398A (ja) | 2010-06-03 |
| WO2003037362A2 (en) | 2003-05-08 |
| US8828934B2 (en) | 2014-09-09 |
| US8957020B2 (en) | 2015-02-17 |
| JP5185962B2 (ja) | 2013-04-17 |
| US20120045452A1 (en) | 2012-02-23 |
| DE60238929D1 (de) | 2011-02-24 |
| US20050080026A1 (en) | 2005-04-14 |
| DK1439863T3 (da) | 2011-03-14 |
| EP1439863B1 (de) | 2011-01-12 |
| DE10294485T5 (de) | 2004-04-29 |
| AU2002363175A1 (en) | 2003-05-12 |
| EP1439863A2 (de) | 2004-07-28 |
| JP2005508170A (ja) | 2005-03-31 |
| US20090170095A1 (en) | 2009-07-02 |
| US8076098B2 (en) | 2011-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE494912T1 (de) | Mnk-kinase-homologe proteine, die an der regulierung der energiehomöostase und dem organellen metabolismus beteiligt sind | |
| EP2213684A3 (de) | Nogo-A-Antikörper für die Behandlung von Alzheimer-Krankheit | |
| WO2003007888A3 (en) | Fat accumulation-modulating compounds | |
| WO2007100366A3 (en) | Quinolone m1 receptor positive allosteric modulators | |
| WO2008002621A3 (en) | Benzyl-substituted quinolone m1 receptor positive allosteric modulators | |
| DE60236322D1 (de) | Verbindungen auf pyrimidin-basis als gsk-3-hemmer | |
| DE69912808D1 (de) | Verwendung von Hymenialdisin und dessen Derivaten zur Herstellung therapeutischer Mittel | |
| MXPA05010937A (es) | Derivados de fenilalanina n-(1,3-tiazol-2-il)amino)carbonil)fenil)sulfonil) y compuestos relacionados para el tratamiento de diabetes. | |
| WO2001009118A3 (en) | Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement | |
| WO2006081230A3 (en) | 3-(indazol-5-yl)-(1,2, 4) triazine derivatives and related compounds as protein kinase inhibitors for the treatment of cancer | |
| SI2527315T1 (sl) | Spojine, sestavki in metode za zdravljenje amiloidnih bolezni in sinukleinopatij, kot so Alzheimerjeva bolezen, diabetes tipa 2 in Parkinsonova bolezen | |
| CY1108514T1 (el) | Παραγωγα 1-φαινυλαλκανεκαρβοξυλικου οξεος για τη θεραπεια νευρογενων ασθενειων | |
| WO2004099168A3 (en) | Substituted carboxylic acids | |
| WO2003040296A8 (en) | Men protein, gst2, rab-rp1, csp, f-box protein lilina/fbl7, abc50, coronin, sec61 alpha, or vhappa1-1, or homologous proteins involved in the regulation of energy homeostasis | |
| WO2005003103A3 (en) | 2, 4, 6-tri-substituted 6-membered heterocycles and their use in the treatment of neurodegenerative diseases | |
| AU2003260436A1 (en) | Pyrimidine compounds | |
| WO2003030922A3 (en) | Bestrophin and bestrophin homologous proteins involved in the regulation of energy homeostasis | |
| WO2003002137A3 (en) | Trp1, mct, or ftz-f1 homologous proteins involved in the regulation of energy homeostasis | |
| WO2003047611A3 (en) | Ptp10d, tec and edtp involved in triglycerid-metabolism | |
| WO2006050359A3 (en) | Pyridazine compounds and methods | |
| DE60231110D1 (de) | Proteindisulfidisomerase und abc-transporter-homologe proteine, die an der regulierung der energie-homeostase beteiligt sind | |
| ATE373661T1 (de) | 1.3.4-triaza-phenalen- und 1,3,4,6- tetraazaphenalen-derivative | |
| ATE554393T1 (de) | Diagnostika und therapeutika für mit adiponectin receptor 2 (adipor2) assoziierten erkrankungen | |
| WO2004035082A3 (en) | Proteins involved in the regulation of energy homeostasis | |
| DE602005025357D1 (de) | Neue 2,4-diaminothiazol-5-onderivate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1439863 Country of ref document: EP |